Evaluation of Tissue Plasminogen Activator Early in the Course of Acute Ischemic Stroke
The National Institute of Neurological Disorders and Stroke (NINDS) has initiated a series of studies to evaluate tissue plasminogen activator (t-PA) as a treatment for acute ischemic stroke . To date, an initial pilot dose determination safety study has been completed and, based on the results of the pilot study, an intermediate randomized controlled trial is about to begin. This report will discuss the design considerations for these trials, the details of the study design of the recently completed pilot study, and some special features of the intermediate-sized controlled clinical trial that will soon begin.
KeywordsIschemic Stroke Acute Ischemic Stroke Intracerebral Hemorrhage Tissue Plasminogen Activator Stroke Symptom
Unable to display preview. Download preview PDF.
- 1.Marler JR, Walker MD (1989) Clinical research on stroke: The NINCDS strategy. Ginsberg MD, Dalton Dietrich W, (eds) Cerebrovascular diseases. Raven Press, New York, pp 17–20Google Scholar
- 2.Meyer JS, Gilroy J, Barnhart ME (1965) Therapeutic thrombolysis in cerebral thromboembolism: randomized evaluation of intravenous streptokinase. In: Siekert RG, Whisnant JP (eds) Cerebral vascular diseases. Grune & Stratton, New York, pp 200–213Google Scholar
- 3.The TIMI Study Group (1985) The thrombolysis in myocardial infarction (TIMI) trial: phase I findings. N Engl J Med 312:932–936Google Scholar